1[2]GamcroP, GrinauxM, SeguimP, etal.claracterizatiou of immunoreaction forms of human osteocalcin generated n vivo and in vitro[J].J Bone Miner Res, 1994,9:255 - 60.
2[1]Garnero P, Dehmas P D. Assessment of the serum levels of bone alkaline phpsphatase with a new immunoradiometric assay in patients vwith metabolic bone disease[J].J Clin Endocrinol Metab, 1993,77:1046-52.[2]GamcroP, GrinauxM, SeguimP, etal.claracterizatiou of immunoreac tion forms of human osteocalcin generated in vivo and in vitro[J].J Bone Miner Res, 1994,9:255 - 60.
3[2]Gamero P, Grinauzx M, Demiaux B, et al. Measurement of serum osteocalcin with a human specific two- site immunoradiometric assay[J].J Bone Miner Res, 1992,7:1389- 97.
4[3]Piedra C, Torres R, Repado A, et al. Serun tartrate - resistant acid pho phatase and bone mineral content in post - roenopausal osteoporosis [ J ]. Calcif Tissue Int, 1989,45:58 - 65.
5[4]Cheung C K, Panesar N S, Haines C, et al. Immunoasay of tartrate - resistant acid phosphatase in senun[J].Clin Clem, 1995,41:679-85.
6[5]BondeM,GarneroP, FledeliusC,etal. Measurementofbonedegrdtion porducts in serum using antibodies reactive with an isonerized form of an 8 amino acid sequence of the C - telopeptide of type I collagen[J].J Bone Miner Res, 1997,12:1028 - 36.
7[6]BonadeM,Qvist P, FledeliusC, etal.Inmunaseayforqusrtifyingtype I collagen degradation products in tuine evaluated[J].Clin Chem, 1994,40:20229.
8[7]Riss B J, Hanseu A M, Jensen K, et al. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture. A 15 - years followup study[J]. Bone, 1996,19:9- 17.
9[8]Camero P, Hausher E, Chapy M C, et al. Bone resorpaion markers prxdict hip fracture risk in elderly wonen: The EPIDOS prospective study[J].J Bone Miner Res, 1996,11;337-47.
10[9]HarrisET, C ettzBJ,C enant H K, etal. Theeffect ofshorttenntreatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmentopausal vomen [J]. J Clin Endocrinol Metab, 1993,76:1399-406.
6Hasegawa J,Nagashima M,Yamamoto M,et al . Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias[J].J Rheumatol,2003;30(3):474-9.
7Insogna K,Mitnick M,Pascarella J,et al .Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women[J].J Bone Miner Res,2002;17(Suppl 2):N108-16.
8Yeh LC, Zavala MC, Lee JC et al . Osteogenic protein-1 and interleukin-6 with its soluble receptor synergistically stimulater at osteoblastic cell differentiation[J].J Cell Physiol,2002;190(3):322-31.
9Ota N,Nakajima T, Nakazawa I,et al .A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density[J].J Hum Genet,2001;46(5):267-72.
10Chung HW, Seo JS,Hur SE,et al .Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women[J].J Hum Genet,2003;48(5):243-248.
